Carbohydrate Metabolism in Hypoglycemia by Kennedy, María L. & Campuzano-Bublitz, Miguel A.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Carbohydrate Metabolism in 
Hypoglycemia
María L. Kennedy and Miguel A. Campuzano-Bublitz
Abstract
Hypoglycemia is generated by mechanisms directly related to an increase in insulin 
secretion, by metabolic disorders that require increased glucose consumption or by a 
deficient metabolic production of glucose by the body. Mechanisms include high glucose 
intake, increased dose of oral hypoglycemic, exogenous administration of insulin, 
metabolic hepatic conditions that lead to an increase in the production of amino acids, 
growing tumors, and in diabetic pregnant woman with abnormal increase in glucose 
and amino acids that end up producing insulin hypersecretion in the newborn. Work 
that requires high glucose expenditure or reduction of insulin antagonist, such as 
cortisol and glucagon, ends up in hypoglycemia. Finally, hypoglycemia is generated by 
metabolic deficit in pathophysiological situations such as defects in enzymatic systems, 
alcoholic hepatitis, and insufficient nutrition. The most characteristic symptoms include 
bulimia, fits of sweating, and tremors due to a strong activation of the sympathetic 
system. Obviously, the CNS is strongly affected by the lack of glucose, which is even 
more complicated because also hypoglycemia leads to a situation of decreased lipolysis 
and ketone bodies that finally seriously compromise the supply of energy to the nervous 
system, producing losses of consciousness, spasms, and even irreversible brain damage.
Keywords: hypoglycemia, increased glucose consumption, hyperinsulinemia, 
exogenous insulin control, uncontrolled diabetes, high glucose expenditure
1. Introduction
The human body is dependent on a tight control of its blood glucose levels to 
ensure normal body function. Survival of individuals, the conscious state, the 
integration of different types of internal and external stimuli, and appropriate 
responses to these stimuli depend on the proper functioning of the central nervous 
system, which puts intense activity in their cells. This requires the consumption 
of oxygen and glucose to obtain the energy that enables the activity of the central 
nervous system (CNS) and keeps the neurons in constant activity [1].
The lack of oxygen causes, in minutes, serious and irreparable damage to the 
central nervous system. However, the lack of glucose is tolerated for a longer time 
because in a deficit situation, the CNS itself makes autonomous adjustments leading 
to inactivity to other non-vital systems of the body and preserves for more time the 
availability of glucose for neurons, and ultimately, in multiday starvation states, it 
substitutes glucose for ketone bodies as a nutrient, which allows life expectancy to 
be extended during fasting. The availability of glucose in people is vital for a good 
quality of life, since it allows the lucid and full functioning of the CNS [2, 3].
The rest of the body’s cells also obtain energy through oxygen and glucose, thus 
enabling metabolism and cellular response. The main source of glucose is through 
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food and specifically depends on the consumption of carbohydrates [4]. The use of 
this carbohydrate in the body is finely regulated by a hormonal system capable of 
always maintaining blood glucose (glycemia) in a concentration ranging from 4.0 
to 5.4 mmol/L (72 to 99 mg/dL) [5]. The human body is prepared to store excess 
of glucose (glycogenesis) and use it in the future (glycogenolysis) when this is 
required and is also able to synthesize glucose from noncarbohydrate precursors 
(substrates) such as amino acids, lactate, and/or glycerol (gluconeogenesis).
The pancreas is the body in charge, among other functions, of maintaining 
glycemia at tolerable levels for the organism, through a system of hormones, where 
insulin is responsible for reducing glycemia in situations of postprandial hypergly-
cemia, while glucagon is responsible for reversing situations of hypoglycemia [6, 7].
2. Carbohydrate metabolism
The carbohydrates present in foods are primarily as polysaccharides that are 
digested by various digestive enzymes. Starch is the most common polysaccha-
ride in foods and is metabolized to maltose by the enzyme alpha amylase present 
in saliva and secreted by the pancreas and this to glucose by the maltases in the 
microvilli of the duodenum. The lactose present in dairy products is metabolized by 
lactases in the intestinal villi to glucose and galactose. Sucrose is also metabolized in 
the intestinal microvilli in glucose and fructose.
The absorption of glucose and galactose is carried out by a secondary active 
cotransport of Na+ to the interior of the enterocyte and from there to the portal 
flow by facilitated diffusion through the GLUT2 glucose transporter (Figure 1). 
Fructose, on the other hand, is only entered into the enterocyte by facilitated diffu-
sion through GLUT5 type transporters located on the apical side, and then they are 
poured into the portal circulation by the same carrier proteins that are also found on 
the basal side of the enterocyte.
The duodenum has a very extensive contact surface, in order to take advantage 
of and absorb as much of these nutrients as possible. The excess, which passes to 
the jejunum, stimulates the release of the glucose-dependent insulinotropic peptide 
(GIP) from the K cells and the glucagon-like peptide type 1 (GLP-1) from the L cells. 
Both stimulate the postprandial release of insulin from the pancreas (Figure 1).
Absorbed glucose increases suddenly in the blood, reaching values above 90 mg/dL,  
and is transported by the GLUT2 carrier protein inside the pancreas where it 
undergoes glycolysis to generate pyruvate. This is used by the mitochondria for 
the production of ATP, which is released into the cytoplasm of the beta cells of the 
pancreas. This excess of ATP desensitizes the ATP-dependent K+ channels that close 
and prevent the migration of K+ ions to the extracellular fluid. With the intracellular 
increase of K+, a depolarization begins; this stimulates the opening of voltage-gated 
calcium channels, which finally ends with the exocytosis of insulin (Figure 1), 
peptide C, and amylin stored in the vesicles into the bloodstream.
The average life of this circulating insulin is 3–5 minutes; its main action is to 
stimulate the uptake of glucose from the bloodstream, mainly by the liver and 
muscle cells. The receptor for insulin in these cells is a tyrosine kinase that, when 
insulin binds, dimerizes and initiates a signaling cascade that rapidly activates the 
phosphatidylinositol-3-kinase (PI3K) pathway that translocates GLUT4 carrier to the 
cell membrane, which allows the massive entry of glucose into the cell. Then the same 
pathway activates the enzyme glycogen synthetase that converts excess of glucose into 
glycogen, activates Acetyl CoA carboxylase that stimulates lipogenesis, and finally, 
in the longer term, activates the pathway of the mitogen-activated kinases (MAP 
kinases) responsible for the expression of the protein synthesis (Figure 1).
3Carbohydrate Metabolism in Hypoglycemia
DOI: http://dx.doi.org/10.5772/intechopen.88362
C peptide is a small molecule that is released when proinsulin is metabolized to 
insulin; in spite of not knowing the specific physiological role of this molecule, in the 
clinical environment, it serves to correlate it with the quantity of insulin synthesized 
by beta cells, because for each molecule of insulin, there is a C peptide, and this 
remains in the bloodstream for a longer time. Amylin, a peptide hormone produced 
in the pancreas, and co-secreted with insulin, and in the brain, improves postprandial 
blood glucose levels by suppressing gastric emptying and glucagon secretion. Amylin 
also acts centrally as a satiation signal, reducing food intake and body weight.
Figure 1. 
Carbohydrate metabolism. Polysaccharides in food are digested, by several enzymes. The absorption is mainly in 
the duodenum. Glucose in the jejunum and ileum stimulates the release of GIP and GLP-1, and postprandial 
release of insulin is stimulated. Glucose in blood reaches the pancreas and undergoes glycolysis to generate 
pyruvate and then ATP; ATP closes K+ channels, and a depolarization begins. Next, voltage-gated calcium 
channels are open and exocytosis of insulin occurs. Insulin binds to its tyrosine kinase receptor and initiates a 
signaling cascade that rapidly produces the massive entry of glucose into the cell.
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Figure 2. 
Regulation of plasma glucose level by insulin and glucagon. Hypoglycemia situations related to diabetes and not 
related to diabetes.
In this way the glycemia values are usually maintained between 70 and 110 mg/dL; 
values below this range produce hypoglycemia that stimulates the release of the 
hormone glucagon from the alpha cells of the pancreas, which promotes anti-insulin 
effects in such a way to re-raise the glycemia values (Figure 2). To this is added a 
third pancreatic hormone, somatostatin, of paracrine regulation which collaborates 
to modulate the release of insulin and glucagon.
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After intense physical activity, the adrenaline released by the stimulus of exer-
cise and the increase of lactate and pyruvate in blood blocks insulin secretion and 
stimulates glucagon to always make glucose available to the body and avoid reactive 
hypoglycemia [6, 8, 9].
3. Glucagon
Insulin secretion from the beta cells of the pancreas is a standard response that 
is directly related to glucose absorbed from food. Thus, if the glycemia increases 
significantly after an intake, this results in a large insulin secretion, while if the 
glycemia remains within the normal range, the stimulus decreases and produces a 
pulsatile insulin secretion that favors the glycemia to remain within the physiologi-
cal range.
In the case that the glycemia falls below 60 mg/dL, the signal to secrete insulin 
weakens and eventually becomes blocked. In contrast, this allows the alpha cells of 
the pancreas to release considerable amounts of glucagon (Figure 2). This hormone 
travels through the portal vein to the liver, where it activates signaling pathways to 
initiate glycogenolysis, which will cause the formation of glucose in the liver so that 
it is released into the bloodstream to immediately increase glycemia. Additionally, 
glucagon increases the recruitment of amino acids to the liver for gluconeogenesis 
that reinforces the effect of glycogenolysis [10].
4. Nondiabetic hypoglycemia
Hypoglycemia is almost always related to a normal or increased amount of insu-
lin as a direct response to glucose intake in food or other pathophysiological factors 
that induce an excessive increase in insulin secretion. A balanced intake of carbohy-
drates, fats, and proteins provides all the nutrients that the body needs for survival, 
but an inadequate diet, deficient in carbohydrates, leads to a reactive hypoglycemia.
The chronic and excessive intake of alcohol produces metabolic alterations in the 
liver that lead to decrease the synthesis and release of glucose from the liver to the 
blood and therefore a decrease in blood sugar (Figure 2).
In the case that the gastric emptying is accelerated (dumping syndrome), due 
for example, to a gastric resection, the digestion and absorption of carbohydrates 
are much faster than normal and also produce the early release of intestinal hor-
mones, including the GIP, which leads to hyperinsulinemia and then the consequent 
hypoglycemia (Figure 2).
The alteration of various functions of the organism has as one of its conse-
quences the reduction of glycemia to critical values, as occurs in the reduction of 
glucocorticoid secretion, such as cortisol, which causes an increase in glycolysis and 
reduced gluconeogenesis from amino acids. This in turn leads to a greater secretion 
of adrenaline that is contrasted in its effects to insulin. On the other hand, thyroid 
hormones regulate many cellular metabolic processes, including hepatic metabo-
lism; therefore, in a situation of hypothyroidism, glycogenolysis and gluconeogen-
esis are drastically reduced (Figure 2).
An alteration in the hepatic metabolism of amino acids, either due to liver failure 
or due to specific enzymatic defects, such as that inducing high leucine level, has an 
effect on insulin secretion, which is increased producing hypoglycemia (Figure 2).
Hepatomegaly is usually caused by an increased hepatic storage of glycogen, 
known as glycogenosis, due to metabolic alterations produced by defective enzymes 
such as glucose-6-phosphatase, in Gierke’s disease, or a debranching enzyme in Cori 
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Forbes disease, a phosphorylase in Hers disease, or a phosphoryl kinase in Huijing’s 
disease. This increase in hepatic glycogen deposition produces a marked hypoglyce-
mia throughout the system (Figure 2).
Aberrations in the expression of certain genes in beta cells make them unable 
to relate the increase in lactate and pyruvate with the state of physical activity and 
therefore induce an increase in insulin secretion that causes significant hypoglyce-
mia in the organism (Figure 2).
The development of tumors, of any type, entails an increase in the need for 
energetic molecules so that cell proliferation is possible. This added to the fact that 
the formation of tumors produces long-term hormonal disorders that keep onco-
logical patients with hypoglycemia for a long time. This effect is compensated by 
lipolysis of the adipocytes in order to make more energetic molecules available, and 
finally the patient develops tumor cachexia [11, 12] (Figure 2).
5. Hypoglycemia related to diabetes
One of the most common causes of hypoglycemia in diabetics occurs as a result 
of the excess administration of insulin or oral hypoglycemic drugs [13, 14]. Patients 
suffering from diabetes mellitus type 1 and whose treatment is based on the exog-
enous administration of insulin must previously corroborate the level of glycemia 
and then adjust the amount of hormone to be administered, considering that 100% 
of the dose, approximately half, is used to immediately regulate the metabolism 
of carbohydrates and the other half is to cover the metabolism at night or fasting 
hours. Therefore, the amount of insulin administered is higher than required, and 
if the necessary precautions are not taken, there is a high probability that the dose 
administered will produce a strong hypoglycemia, especially during sleep hours, 
known as the Somogyi effect. The amount of insulin units to administer considers 
the actual value of the glycemia, which forces the patient to measure it, compare 
and extract the difference with the theoretical optimum value of 120 mg/dL of fast-
ing blood glucose, and divide it by the factor 50, since one unit of insulin reduces 
blood glucose by approximately 50 mg/dL (Figure 2).
Even so, the correct amount of insulin to be administered must also be defined 
by other factors, such as the total amount of carbohydrates ingested with food, the 
type of insulin to be administered, and the recommendations of the treating medi-
cal professional.
Oral hypoglycemic agents, used in the treatment of type 2 diabetes mellitus, can 
also lead to a strong insulin secretion. The large family of sulfonylureas (chlorprop-
amide, glibenclamide, gliclazide, glisentide, glipizide, gliquidone, and glimepiride) 
and the secretagogue glinides (repaglinide and nateglinide) are characterized by 
the ability to induce hypoglycemia and cause weight gain, due to the decrease in the 
lipolysis in the patients who use it for their treatment (Figure 2).
Another interaction with a high probability of producing hypoglycemia is the 
concomitant treatment with incretin analogues (exenatide) and inhibitors of dipep-
tidyl peptidases (vildagliptin) because it significantly increases the pancreatic β cell 
mass, which leads to greater insulin secretion and even with high risks of producing 
pancreatitis (Figure 2).
Diabetic women during pregnancy have poor control of carbohydrate metabo-
lism and thus coexist with high blood levels of glucose and amino acids; this 
long-term hyperglycemia is transferred to the fetus and forces hyperplasia in fetal 
pancreatic beta-cell tissue, which finally predisposes the newborn to a greater secre-
tion of insulin and the consequent hypoglycemia [15–17] (Figure 2).
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6. Clinical manifestations
The decrease in blood sugar below 60 mg/dL is known as hypoglycemia. In a 
first phase, this leads to a stimulation of the parasympathetic autonomic nervous 
system that causes a sensation of hunger and leads the patient to bulimia. In the 
second phase, the sympathetic autonomic nervous system is stimulated, producing 
the secretion of important quantities of catecholamines that activate their receptors 
in important target organs such as the heart, which produces an acceleration of the 
heartbeat, in sweat glands increases the production of sweat, and in the somatic 
nervous system causes tremors. It is frequent double vision, difficulty concentrat-
ing, loss of ease of speech, and confusion states. A hypoglycemia below 20 mg/dL 
induces a coma (Figure 3).
The most serious effect is a marked cognitive dysfunction, since the supplies 
of nutrients, glucose, and ketones to the nervous system are markedly diminished; 
produce loss of consciousness, brain spasms, and epileptic seizures in children; and 
can potentially lead to irreversible neuronal damage [18, 19].
7. Treatment of hypoglycemia
The treatment will depend on the degree of hypoglycemia that the patient devel-
ops. That, which does not pass the first phase of the clinical manifestation, requires 
rapid replacement of glucose from food. The CNS itself is the one that predisposes 
to this action by triggering bulimia in the patient. Most of the foods available to 
patients contain abundant amounts of carbohydrates that help to remedy hypogly-
cemia (Figure 3).
Figure 3. 
A summary of glycemia levels and clinical consequences.
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In cases where hypoglycemia is more pronounced, it is necessary to administer 
pharmaceutical preparations containing glucose, but this treatment should be 
monitored to avoid the opposite effect, i.e., hyperglycemia, especially in diabetic 
patients who triggered hypoglycemia due to excess insulin.
In patients with severe hypoglycemia crisis, which affects the conscience, it 
is necessary to act urgently administering parenteral glucagon preparations, or 
glucose will be administered directly, and the rapid recovery of the patient will be 
monitored [14, 15, 19–21] (Figure 3).
8. Conclusion
Hypoglycemia is generated by mechanisms directly related to an increase in 
insulin secretion or by metabolic disorders that require increased glucose consump-
tion or by a deficient metabolic production of glucose by the body.
Hyperinsulinemia can be produced by various mechanisms, including high 
glucose intake in foods, an increased dose of oral hypoglycemic agents, as well 
as exogenous insulin administration without control, liver metabolic conditions 
that lead to an increase in the production of amino acids by this organ, tumors in 
permanent growth, and an abnormal increase in glucose and amino acids in the case 
of uncontrolled diabetic pregnant women that end up producing insulin hyperse-
cretion in the newborn.
Work that requires high glucose consumption, more than what the body can 
supply, ends up in situations of hypoglycemia, as well as when there is a decrease 
in hormone antagonists to insulin, such as cortisol or glucagon. The state of hypo-
glycemia is generated by metabolic deficit in pathophysiological situations such as 
defects in enzymatic systems, alcoholic hepatitis, and insufficient diet.
The most characteristic symptoms include bulimia, fits of sweating, and tremors 
due to a strong activation of the sympathetic system. Primarily, the CNS is strongly 
affected by the lack of glucose, which is even more complicated because also hypo-
glycemia leads to a situation of decreased lipolysis and ketone bodies that finally 
seriously compromise the supply of energy to the central nervous system, produc-
ing loss of consciousness, spasms, and even irreversible brain damage.
The treatment of less severe hypoglycemic patients is preferably carried out with 
the rapid administration of carbohydrate-rich foods. For more serious cases, the 
use of pharmaceutical products that supply carbohydrates is resorted to, but the 
glycemia must be monitored to avoid hyperglycemia. Those patients who are much 
compromised, with loss of consciousness, should receive parenteral glucagon or 
glucose in an urgent way to recover them.
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